This digest covers key developments from Vaxcyte, AbbVie, Genmab, AstraZeneca, Summit Therapeutics and Eli Lilly, spanning pivotal Phase 3 readouts, a large equity transaction and regulatory and business-development updates across the sector.This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

TWiV explains a study testing how 16 hypothesized social and environmental drivers impact disease outbreaks, concluding that infectious disease spillover and emergence are multi-causal, and that no one-size-fits-all strategy can prevent epidemics and pandemics, and an analysis of Myotis bats, which shows that their remarkable longevity and immunity are linked through pleiotropic adaptations to viruses and aging-related disease. Hosts: Vincent Racaniello, Alan Dove, and Angela Mingarelli Subscribe

Container closure integrity (CCI) is a critical element of sterile product quality, but evaluating a CDMO’s CCI capabilities requires more than confirming that testing is available.The appropriate approach depends on the drug product, container closure system, manufacturing process, lifecycle risks, and applicable regulatory requirements. For pharmaceutical companies selecting or qualifying a CDMO, understanding how a manufacturing partner approaches these variables can provide useful insight into

Episode SummaryThis month on the Deep-Sea Podcast, we speak with Anne Helene Tandberg, a researcher from the University Museum of Bergen who specializes in amphipods and curated the deep-sea exhibit at the University Museum of Bergen, Norway. Check out our lovely new website where you can find more detailed notes, images and links to the wider reading. In this episode… Welcome back to the Deep-Sea Podcast, your punk take on all things deep sea! Alan is living day 56 on a boat, and feeling

Delayed Friday edition, recorded October 2. Lilly's Jaypirca (pirtobrutinib) gains first-line approval for adults with CLL/SLL without a known 17p deletion—but how does a trial against older chemotherapy guide today's treatment choice? Novartis agrees to $575 million upfront for Abogen's early-stage RNA medicine ABO2203, with closing still pending and autoimmune benefit unproven. Also: Pfizer's Litfulo (ritlecitinib) advances toward vitiligo filings; Biogen reports longer-term

Get in touch to share sheeping stories or questions anytime! We love hearing from our listeners and in this episode we answer some interesting questions from listeners on routine hoof care for sheep and how and when to castrate lambs. Andrew recently attended the Irish Lanark society sale in Roscommon and his buying strategy paid off big time! Thanks for listening! Thank you for supporting our pod! Sign up via our sheep supporters tab ! https://www.buzzsprout.com/954910/supporter...

This digest covers key developments from Shionogi, Alector and Eli Lilly, including corporate acquisitions, a Parkinson’s disease licensing deal and a first-line label expansion, alongside broader coverage across the sector.This brief was generated using the SOZO Intuition platform, providing personalized biotech intelligence and catalyst tracking to help life sciences leaders make better decisions.

In this classic episode of Stuff to Blow Your Mind, Robert and Joe discuss the idea of Egyptian tomb curses, how they actually factored into ancient Egyptian practices and where the myth of the Pharaoh's curse meets reality. (originally published 9/30/2025)See omnystudio.com/listener for privacy information.

Planetterrian Daily 🌍 Planetterrian Daily - Science, Longevity & Health Discoveries A single mitochondrial protein links the circadian clock directly to brown fat metabolism in new Science findings. Top 15 Science & Health Discoveries Skin functions as dynamic organ beyond appearance — Yahoo Creators Skin performs immune surveillance, temperature regulation, vitamin D synthesis, and microbiome support. ... Sources: creators.yahoo.com · bioengineer.org · science.org · nytimes.com ·

Business Creativity and Innovation in Pharma 4.0What happens when one of the world’s most highly regulated industries embraces creativity, experimentation, artificial intelligence, and digital technologies? In this episode of Center of Excellence - Pharma 4.0, we explore how business creativity and innovation can reshape the pharmaceutical industry—not by compromising scientific rigor or regulatory compliance, but by creating smarter, safer, faster, and more adaptive ways of working. The discussion

In his weekly clinical update, Daniel Griffin and Vincent Racaniello continue their ongoing exasperation over 5 deaths in Pennsylvania associated with measles infections, the absurdity of RFK Jr.'s statement that AI is better informed than physicians, the outbreak of cholera, more deaths by raw milk products, spread of dengue virus in Florida, Ebola in DRC, refusal to acknowledge the benefits of the HBV vaccine birth dose, how TORCH agent infections impact neurodevelopment and may lead to increase

Rob Dodge says AI has made him an expert Python programmer, even though he never took a class in it. But does having new capabilities change what it means to be a scientist?Dr. Chad Briscoe sits down with Dr. Robert “Rob” Dodge at the AAPS National Biotechnology Conference in San Diego to discuss how artificial intelligence and machine learning are changing pharmaceutical research.Thank you to our sponsorsTruTechnologies provides real-time clinical trial oversight, helping research teams improve

If the sun didn't power the photosynthesis of green plants, we wouldn't be breathing right now. And without the finely tuned properties of water, Earth would be a frozen, lifeless wasteland. Coincidence? Or is something else at work? On this classic episode of ID The Future out of the archive, host Andrew McDiarmid continues his ongoing series with Dr. Jonathan McLatchie unpacking the many features of our planet and the cosmos that allow for advanced life like ours to exist. Here, the discussion

An outbreak of Ebola disease caused by the Bundibugyo virus remains in a period of intense transmission, in the Democratic Republic of the Congo. Since it's first detection in May, 6757 cases have been confirmed across 6 provinces of the DRC, along with 20 cases in Uganda and one in France (as of September 8). A crude case fatality ratio of 48% underscores the severity of the disease and the ongoing challenges towards case detection, clinical care and, ultimately, interruption of transmission

Foghorn Therapeutics and Eli Lilly discontinue their SMARCA2 degrader program, Novartis licenses Abogen's autoimmune mRNA therapy while AstraZeneca, Daiichi Sankyo, and Summit Therapeutics team up on a breast cancer combination trial, and Corxel's Bo Liang makes the case for oral GLP-1 therapies.

On this week's episode, Graig Suvannavejh, Sam Fazeli, Eric Schmidt, and Brian Skorney open with a look at the public markets, noting the XBI is up 27% year-to-date but down about 9% since its August high. The co-hosts then touched on Oura's pulled IPO, seeing little read-through for the broader biotech space. In deals, Sanofi and Regeneron extended their antibody collaboration for $1 billion upfront and up to $7 billion in milestones, while AstraZeneca and Daiichi Sankyo struck deals with

Thorne et al., Proceedings of the National Academy of Sciences - GLP-1 receptor agonists such as semaglutide produce large weight loss, but part of what is lost is lean mass, energy expenditure falls, and weight tends to return when treatment stops. This study tests a complementary idea in mice: switching on heat-producing fat by silencing ZFP423, a repressor of brown and beige fat identity, with an adipose-targeted antisense oligonucleotide. The RNA drug

Is "AI is dangerous" a warning, or the world's best marketing line?This episode is brought to you by AgelessRx, where aging becomes a puzzle that can be solved. The mission is to help you live longer and healthier by adding more life to your years through science-backed solutions and personalized care. Learn more at agelessrx.com/beyond-tomorrow.On this episode of Beyond Tomorrow, I sit down with Thore Graepel, co-creator of AlphaGo and former researcher at Google DeepMind. I asked him straight up

TWiP explains a single-cell analysis of immune cells in the blood of dogs with canine leishmaniosis, providing a detailed picture of how the immune response changes as the disease progresses. Hosts: Vincent Racaniello, Daniel Griffin, and Christina Naula Subscribe (free): Apple Podcasts, RSS, email Links for this episode Join the MicrobeTV Discord server Single immune cell atlas of canine leishmaniosis (iScience) Clinical staging in CanL (LeishVet) TWiP study – information and survey Become

While falls can happen to anyone, older adults are more likely to experience serious injuries as a result. That's why falls prevention is an important public health issue for all of us, not just for older adults but also for their families, caregivers, and communities. In this episode, Dr. Carol Petrie, a board certified expert in geriatric physical therapy and falls prevention talks about the best ways to reduce our risk of falling, when we should begin thinking about it, advice for caregive...